| Survival: | 9.6 months |
| Toxicity Grade: | 5 |
| Treatments: | Chemotherapy |
| Drugs: | |
| Country: | United States |
| City/State/Province: | Chicago, Illinois |
| Hospital: | University of Chicago Medical Center |
| Journal: | Link |
| Date: | 11/1999 |
| Description: |
| Patients: This Phase II study involved 20 patients with malignant mesothelioma who could not be treated by surgery or radiation alone. Treatment: The treatment consisted of administration of the drug edatrexate. Toxicity: Four patients died without documentation of progressive disease. These deaths involved neutropenic sepsis, cardiac arrest, and respiratory failure from progressive mesothelioma. Grade 3-4 toxicities included hematologic, infection, nausea, emesis, muscositis, esophagitis/dysphagia, dermatologic, anorexia, malaise/fatigue, cardiac, pulmonary, renal, hepatic, and neurologic. Results: The median survival duration was 9.6 months. |